

Author(s):

Question: Allopurinol compared to Placebo or Conventional group for hyperuricemia in diabetes mellitus

Setting:

Bibliography: Allopurinol for hyperuricemia in diabetes mellitus. Cochrane Database of Systematic Reviews [Year], Issue [Issue].

Certainty assessment							No of patients		Effect		Certainty	Importance
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Allopurinol	Placebo or Conventional group	Relative (95% CI)	Absolute (95% CI)		
24-hour urine protein												
4	randomised trials	serious	not serious	not serious	not serious	none	158	150	-	MD 493.61 lower (679.61 lower to 307.61 lower)	⊕⊕⊕○ Moderate	
subgroup analysis- Serum uric acid												
10	randomised trials	serious	serious	not serious	not serious	none	446	420	-	SMD 2.32 lower (3.29 lower to 1.35 lower)	⊕⊕○○ Low	
subgroup analysis- Serum uric acid - Allopurinol vs Placebo												
4	randomised trials	serious	serious	not serious	not serious	none	165	163	-	SMD 1.05 lower (1.42 lower to 0.68 lower)	⊕⊕○○ Low	
subgroup analysis- Serum uric acid - Allopurinol vs Conventional group												
6	randomised trials	serious	serious	not serious	not serious	none	281	257	-	SMD 3.23 lower (4.88 lower to 1.59 lower)	⊕⊕○○ Low	
Serum creatinine												
5	randomised trials	serious	not serious	not serious	not serious	none	250	231	-	SMD 0.45 lower (0.96 lower to 0.06 higher)	⊕⊕⊕○ Moderate	
Serum creatinine - treatment duration ≥ 6 months												
3	randomised trials	serious	not serious	not serious	not serious	none	191	174	-	SMD 0.51 lower (1.33 lower to 0.32 higher)	⊕⊕⊕○ Moderate	
Serum creatinine - treatment duration < 6 months												
2	randomised trials	serious	not serious	not serious	not serious	none	59	57	-	SMD 0.41 lower (0.77 lower to 0.04 lower)	⊕⊕⊕○ Moderate	

CI: confidence interval; MD: mean difference; SMD: standardised mean difference